Advances in™ ALK+ NSCLC: Leveraging Evidence and Patient Characteristics to Inform Treatment

Release Date: November 15, 2021
Expiration Date: November 15, 2022

Activity Overview

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.
 

Target Audience

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Determine optimal testing strategies and impact on decision making in the front line and subsequent therapeutic management of patients with advanced ALK-positive NSCLC
• Evaluate emerging clinical trial evidence examining the role of ALK-targeted therapies in the management of first- and later-line therapy in NSCLC
• Describe treatment sequencing strategies and care planning for patients with advanced ALK-positive NSCLC to address treatment resistance and manage brain metastases
• Outline preemptive mitigation and management strategies for adverse events associated with ALK inhibitors in multiple lines of care among patients with advanced NSCLC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
 

Faculty

D. Ross Camidge, MD, PhD
Joyce Zeff Chair in Lung Cancer Research
Director of Thoracic Oncology
University of Colorado
Aurora, CO
 

Disclosures: Advisory role: Ad hoc advisory boards/consultations: AbbVie, Amgen, AnHeart Therapeutics, Apollomics (SRC), AstraZeneca (SRC/SC), Beigene (DSMC), Bio-Thera Solutions (DSMB), Blueprint Medicines, Daiichi-Sankyo (ILD adjudication committee), Elevation Oncology (SRC), Eli Lilly (DSMB and NCCN), EMD Serono, Helsinn (DSMB), Janssen, Kestrel LifeSciences (SAB, Shares), Mersana Therapeutics, Nuvalent (SAB), Puma (NCCN), Ribon Therapeutics, Roche/Genentech, Sanofi, Seattle Genetics, Takeda, Turning Point. Research funding: Inivata. Company sponsored trials at institution (PI roles): AbbVie, AstraZeneca, Dizal Pharma, Inhibrx, Karyopharm, Pfizer, Phosplatin Therapeutics, PsiOxus Therapeutics, Rain Therapeutics, Roche/Genentech, Seattle Genetics, Takeda, Turning Point.
 

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.